Literature DB >> 6313380

Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance.

P J McNamara, M Gibaldi, K Stoeckel.   

Abstract

Guidelines presented previously for the analysis of plasma concentration versus time data for a drug exhibiting concentration-dependent plasma protein binding were successfully applied to the distributional parameters of a new cephalosporin, ceftriaxone. This approach provided several striking observations when the pharmacokinetics of ceftriaxone in a healthy and uremic population were re-examined. First, the parameter -fp converted the apparent dose-dependent distributional terms of ceftriaxone into a function of the concentration-dependent plasma protein binding. Second, a strong correlation between the term VUSS and the reciprocal of -fp was established within each of the two populations. While this -fp term accounted for the variability within the respective populations due to ceftriaxone-albumin binding differences, it did not account for all of the distributional differences between the two populations. The present analysis revealed that the altered physiologic state of uremia (larger plasma volumes and interstitial to intravascular albumin ratios), in addition to differences in plasma protein binding, dictated the distribution of ceftriaxone in healthy and uremic subjects. Furthermore, the binding-disposition model which accounts for the presence of plasma proteins outside the vascular space, was established to be appropriate in describing the distribution of ceftriaxone.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313380     DOI: 10.1007/bf01037956

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

Review 1.  Factors affecting drug metabolism.

Authors:  J R Gillette
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

2.  Effect of saturable binding on the pharmacokinetics of drugs: a simulation.

Authors:  S Oie; T W Guentert; T N Tozer
Journal:  J Pharm Pharmacol       Date:  1980-07       Impact factor: 3.765

3.  Accumulation kinetics of drugs with nonlinear plasma protein and tissue binding characteristics.

Authors:  P J McNamara; J T Slattery; M Gibaldi; G Levy
Journal:  J Pharmacokinet Biopharm       Date:  1979-08

4.  Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Single-dose ceftriaxone kinetics in functionally anephric patients.

Authors:  K Stoeckel; P J McNamara; G Hoppe-Seyler; A Blumberg; E Keller
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

6.  Fraction unbound in interstitial fluid.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

7.  Fitting straight lines when both variables are subject to error.

Authors:  D S Riggs; J A Guarnieri; S Addelman
Journal:  Life Sci       Date:  1978 Apr 3-17       Impact factor: 5.037

8.  Correction of protein binding defect in uremic sera by charcoal treatment.

Authors:  W A Craig; M A Evenson; K P Sarver; J P Wagnild
Journal:  J Lab Clin Med       Date:  1976-04

9.  Body fluid composition in chronic renal failure.

Authors:  J H Bauer; C S Brooks
Journal:  Clin Nephrol       Date:  1981-09       Impact factor: 0.975

10.  Albumin metabolism and gastrointestinal loss of protein in chronic renal failure.

Authors:  S V Johansson; I O Odar-Cederlöf; L O Plantin; P O Strandberg
Journal:  Acta Med Scand       Date:  1977
View more
  15 in total

Review 1.  Nonlinear Protein Binding: Not What You Think.

Authors:  Amelia N Deitchman; Ravi Shankar Prasad Singh; Hartmut Derendorf
Journal:  J Pharm Sci       Date:  2018-04-04       Impact factor: 3.534

2.  Volumes of distribution and mean residence time of drugs with linear tissue distribution and binding and nonlinear protein binding.

Authors:  H Cheng; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

3.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

4.  Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 6.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 7.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

8.  Characteristics of ceftriaxone binding to immunoglobulin G and potential clinical significance.

Authors:  H Sun; M S Chow; E G Maderazo
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

9.  Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy.

Authors:  W L Hayton; R Schandlik; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Age-associated changes in ceftriaxone pharmacokinetics.

Authors:  W L Hayton; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.